LeonaBio Appoints Three Directors with Oncology and Neurology Development Expertise

Governance depth at clinical-stage biotechs often signals where pipeline risk is being actively managed, and LeonaBio, Inc. (NASDAQ: LONA) has moved to reinforce its board with three appointments carrying direct oncology, neurology, and capital markets credentials. Fred Callori, J.D., Natalie Holles, and Peter B. Silverman, J.D. joined the board effective May 5, 2026, coinciding with the retirement of founding-era director John Fluke, Jr., who stepped down after more than a decade of service.

For regulatory and clinical operations leads tracking clinical-stage biotech governance, the profile of the incoming directors reflects a deliberate alignment with late-preclinical and early-clinical execution demands. Callori brings life sciences investment and corporate development experience from Perceptive Advisors and Xontogeny, alongside prior public-company board service at Astria Therapeutics and Landos Biopharma. Holles, currently CEO of Aura Biosciences, carries operational leadership across Audentes Therapeutics, Third Harmonic Bio, and earlier roles at Hyperion Therapeutics and Genentech, spanning rare disease, genetic medicines, and immunotherapy. Silverman's background, also noted by the company as complementary to its strategic positioning, rounds out a board now weighted toward drug development execution and capital markets navigation.

President and CEO Mark Litton, Ph.D., cited the incoming directors' collective experience across oncology and neurology settings as directly aligned with LeonaBio's pipeline advancement priorities. The company has not disclosed specific pipeline milestones or regulatory submission timelines in connection with the appointments, but the governance restructuring is consistent with clinical-stage companies preparing for IND-enabling or Phase transition activity where board-level scientific and operational oversight carries regulatory weight.

The board transition also closes a chapter on Fluke's tenure, which spanned LeonaBio's formative years since 2014. Litton acknowledged Fluke's role in shaping the company's current structure, though no further detail on succession planning or committee assignments for the new directors was provided in the announcement.

The measurable indicator to watch is whether LeonaBio files any clinical or regulatory submissions within the next two reporting cycles, which would confirm whether this governance refresh is pacing ahead of a defined regulatory inflection point.

Source: GlobeNewswire via LeonaBio press release, May 7, 2026.